CellCura has inked an agreement with IDT Biologika for the testing and adaptation of its protein-free (PF) media for the production of cell lines for vaccine manufacturing.
Roche has launched a new analysis platform designed to help bio manufacturers monitor and optimise production operations.
Advantar Labs has allied with DavosPharma to accelerate clients’ development programmes with chemistry and analytical services.
Vivalis cut its operating loss after demand for its vaccine production cell line drove triple-digit revenue growth.
vivoPharm has extended its oncology offering after striking up an alliance with MPI Research.
in-PharmaTechnologist presents a roundup of the latest drug delivery research, including bone marrow targeting nanoparticles and an imaging-treatment combo.
UK preclinical contractor Cyprotex says H1 profits were hit by the loss of it biggest customer, but is upbeat on revenue growth and potential of in vitro toxicity testing business.
in-PharmaTechnologist presents its latest round-up of the movers and shakers within the pharmaceutical industry, including appointments from AAPS, SurModics, Diamedica, and Sirona Biochem.
Irvine Scientific has begun shipping from the cell culture media plant it built to expand into Asia and give clients the security of a second source.
Unilife has developed the world’s first multi-chamber prefilled syringes that have an in-built safety mechanism.
US bioreactor maker PBS Biotech has bought medical device focused CMO Integrity CMI to expand its manufacturing capacity
Japanese drugmaker Takeda has been awarded JPY24bn ($313m) to develop and a cell culture influenza vaccine and establish a commercial-scale production facility.
Catalent is to buy clinical trial supply assets from Aptuit for $410m (€285m) as it adds scale to handle the shift to preferred provider relationships.
in-PharmaTechnologist presents a roundup of recent ingredient and formulation research, including improved API impurity detection and a simple step to boost stability.
Repligen should consider selling its bioprocessing unit, which sells materials used in mAb production, to make best use of its assets, a shareholder suggests.